NXTC Price / Book | NEXTCURE, INC

NextCure, Inc. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

NextCure, Inc. price/book ratio for the quarter ending 2026-06-30 was 0.54, a 1382.71% increase year-over-year.
NextCure, Inc. price/book ratio for the quarter ending 2026-03-31 was 1.41, a 51.28% decline year-over-year.
NextCure, Inc. price/book ratio for the quarter ending 2025-12-31 was 1.44, a 336.21% increase year-over-year.
NextCure, Inc. price/book ratio for the quarter ending 2025-09-30 was 0.66, a 89.10% decline year-over-year.
NextCure, Inc. price/book ratio for fiscal 2026 was 0.54.
NextCure, Inc. price/book ratio for fiscal 2025 was 1.44, a 336.21% increase from fiscal 2024.
NextCure, Inc. price/book ratio for fiscal 2024 was 0.33, a 90.11% decline from fiscal 2023.
NextCure, Inc. price/book ratio for fiscal 2023 was 3.34, a 18.93% increase from fiscal 2022.

Available history: 2019-06-30 to 2026-06-30
Data captured: 2026-06-30

Historical Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	0.54	$6.59M	$12.15M
2026-03-31	1.41	$37.59M	$26.72M
2025-12-31	1.44	$50.27M	$34.94M
2025-09-30	0.66	$15.68M	$23.65M
2025-06-30	0.04	$1.08M	$29.65M
2025-03-31	2.89	$161.32M	$55.86M
2024-12-31	0.33	$21.59M	$65.47M
2024-09-30	6.08	$459.92M	$75.59M
2024-06-30	6.25	$533.78M	$85.44M
2024-03-31	7.54	$746.7M	$99.05M
2023-12-31	3.34	$381.71M	$114.42M
2023-09-30	3.41	$430.96M	$126.45M
2023-06-30	4.34	$601.34M	$138.43M
2023-03-31	3.2	$493.28M	$154.2M
2022-12-31	2.81	$469.95M	$167.53M
2022-09-30	5.04	$915.71M	$181.54M
2022-06-30	7.9	$1.57B	$198.2M
2022-03-31	7.56	$1.62B	$213.94M
2021-12-31	8.54	$1.99B	$233.39M
2021-09-30	9	$2.23B	$248.23M
2021-06-30	10.09	$2.66B	$263.6M
2021-03-31	11.88	$3.32B	$279.16M
2020-12-31	12.28	$3.61B	$293.72M
2020-09-30	9.47	$2.91B	$307.34M
2020-06-30	21.99	$7.08B	$321.92M
2020-03-31	36.9	$12.24B	$331.76M
2019-12-31	57.82	$18.59B	$321.48M
2019-09-30	49.33	$8.42B	$170.65M
2019-06-30	22.86	$4.08B	$178.6M

Annual Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	0.54	$6.59M	$12.15M
2025-12-31	1.44	$50.27M	$34.94M
2024-12-31	0.33	$21.59M	$65.47M
2023-12-31	3.34	$381.71M	$114.42M
2022-12-31	2.81	$469.95M	$167.53M
2021-12-31	8.54	$1.99B	$233.39M
2020-12-31	12.28	$3.61B	$293.72M
2019-12-31	57.82	$18.59B	$321.48M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
TherapeuticsMD, Inc. (TXMD)	United States	$0.024B	-117.87
AYTU BIOPHARMA, INC (AYTU)	United States	$0.025B	-1.62
ARTELO BIOSCIENCES, INC. (ARTL)	United States	$0.023B
Cocrystal Pharma, Inc. (COCP)	United States	$0.022B
ATOSSA THERAPEUTICS, INC. (ATOS)	United States	$0.021B	-0.52
KYNTRA BIO, INC. (KYNB)	United States	$0.028B	0.17
Transcode Therapeutics, Inc. (RNAZ)	United States	$0.029B	-0.12
Hepion Pharmaceuticals, Inc. (HEPA)	United States	$0.029B	-0.62
Neuphoria Therapeutics Inc. (NEUP)	United States	$0.020B	-1.77
Marker Therapeutics, Inc. (MRKR)	United States	$0.020B	-2.86